Moretta L., Pharmaceutical Drug Lifecycle: A Comprehensive Scientific Review of Research and Development Phases, Attrition Rates, and Global Disparities, Preprints, 2026
This analysis provides an in-depth overview of the pharmaceutical drug lifecycle, detailing the various research and development phases, including discovery, preclinical testing, clinical trials, and post-market surveillance. It also examines attrition rates at each stage (such as the 95% preclinical), highlighting the high failure rates and the significant financial and temporal investments required. Additionally, the review discusses global disparities in drug development, touching on how different regulatory environments, economic conditions, and healthcare infrastructures impact the process worldwide. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

FDA, Roadmap to Reducing Animal Testing in Preclinical Safety Studies | FDA
The official FDA roadmap outlines strategies to reduce animal testing in preclinical safety studies by promoting the use of alternative methods such as in vitro assays, computational models, and human-relevant in vivo models. It emphasizes the importance of scientific validation, regulatory acceptance, and international collaboration to enhance the safety and efficacy evaluations of new drugs while minimizing the reliance on animal testing. ↩︎ ↩︎ ↩︎

IntuitionLabs, Why Drug Development Takes Decades: Process & Challenges | IntuitionLabs, 2026
Drug development typically spans over a decade due to the rigorous, multi-stage process required to ensure safety and efficacy before reaching patients. This timeline involves extensive preclinical research, followed by three distinct phases of clinical trials (involving hundreds to thousands of volunteers) that test dosage, safety, and effectiveness, all while facing significant challenges like high failure rates (often exceeding 90% in later stages), regulatory hurdles, and immense financial costs that can reach billions of dollars per approved drug. ↩︎ ↩︎ ↩︎

Marshall LJ, Bailey J, Cassotta M, et al., Poor Translatability of Biomedical Research Using Animals — A Narrative Review, Altern Lab Anim, 2023
This high-impact review argues that biomedical research relying heavily on animal models suffers from poor translatability to humans, leading to frequent failures in clinical trials and significant delays in drug approval. The authors highlight fundamental biological and physiological differences between species—such as metabolism, disease progression, and immune responses—that cause results observed in animals to often fail when tested in human populations. Consequently, the paper advocates for a shift toward more human-relevant research models, including organ-on-a-chip technologies and advanced computational simulations, to improve the predictive accuracy of preclinical studies and reduce the high attrition rates in the drug development pipeline. ↩︎ ↩︎ ↩︎ ↩︎

Franzen N, van Harten WH, Retèl VP, Loskill P, van den Eijnden-van Raaij J, IJzerman M, Impact of organ-on-a-chip technology on pharmaceutical R&D costs, Drug Discovery Today, 2019
This study evaluates the potential of organ-on-a-chip (OoC) technology to significantly reduce pharmaceutical R&D costs (estimated 10-26%) by offering a more predictive and human-relevant alternative to traditional animal models. The authors argue that while the initial investment in developing OoC systems is substantial, their ability to accurately model complex human physiology can drastically lower failure rates in preclinical phases, thereby saving billions of dollars later in the pipeline where attrition is highest. By enabling earlier identification of toxicity and efficacy issues specific to human biology, OoC platforms promise to streamline drug discovery, shorten development timelines, and ultimately make the creation of new medicines more cost-effective and efficient. ↩︎ ↩︎ ↩︎

Forbes, The Truly Staggering Cost Of Inventing New Drugs
This striking article breaks down the immense financial burden of bringing a new drug to market, estimating the total cost to reach the U.S. market at over $2 billion (some as high as $12 billion) when accounting for the full pipeline, including failed candidates. It highlights that a significant portion of these expenses is attributable to the high failure rate in clinical trials and the need to compensate for unsuccessful projects, illustrating why pharmaceutical companies are increasingly motivated to adopt cost-effective in silico and in vitro screening methods that can identify non-viable compounds earlier and reduce the staggering financial losses associated with late-stage trial failures. ↩︎ ↩︎

Humane World, Costs of animal and non-animal testing | Humane World
According to Humane World, physical animal testing laboratories incur significantly higher operational costs compared to automated non-animal alternatives. The report highlights that the massive overhead associated with maintaining live animal facilities—covering specialized infrastructure, animal care, and regulatory compliance—creates a substantial financial penalty that automated, scalable testing methods effectively eliminate, making ethical alternatives not only morally preferable but also economically advantageous. ↩︎ ↩︎ ↩︎ ↩︎

Emulate Inc., What are Organ-Chips?
This company describes organ-on-a-chip technology as a revolutionary platform that uses living human cells to recreate the micro-environment and physiological functions of human organs within a miniature, lab-grown device. Unlike traditional petri dishes, these chips integrate multiple cell types with fluid flow and mechanical cues to mimic the complex interactions and dynamic conditions found in the human body, enabling researchers to study disease mechanisms, drug toxicity, and personalized medicine with unprecedented accuracy and ethical superiority over animal models. ↩︎ ↩︎ ↩︎

Song S, Jeong S, State-of-the-art in high throughput organ-on-chip for biotechnology and pharmaceuticals, Clin Exp Reprod Med, 2025
This is a peer-reviewed study which evaluates the current landscape of high-throughput organ-on-chip (HOO-Chip) systems, emphasizing their critical role in advancing biotechnology and pharmaceutical development. The authors highlight how these advanced platforms integrate multiple organ models into parallelized, automated arrays to simultaneously assess drug efficacy and toxicity with unprecedented efficiency, significantly reducing reliance on animal testing. By addressing key challenges in scalability, standardization, and data integration, the paper positions high-throughput organ chips as the future standard for precision medicine and accelerated drug discovery pipelines. ↩︎ ↩︎ ↩︎

Phorum, FDA’s emerging framework to reduce animal testing: Implications for drug development timelines, cost, and clinical strategy | pharmaphorum
This is a strategic assessment of the regulatory pivot following the FDA Modernization Act 2.0 and its impact on clinical trial acceleration. The FDA’s emerging framework to reduce animal testing is reshaping drug development by mandating the use of validated non-animal methods (NAM) for toxicity screening earlier in the pipeline. This strategic shift aims to cut development timelines and costs by preventing late-stage failures caused by poor translation from animal models to human trials, while simultaneously addressing ethical concerns. By integrating advanced computational models, organ-on-chip technologies, and AI-driven predictions, the new regulatory approach encourages a more efficient, precise, and humane pathway from laboratory discovery to clinical approval. ↩︎ ↩︎

How Much Blog, How much money is spent on animal testing every year? | HowMuchBlog
The global cost of animal testing is staggering, with estimates suggesting that billions of dollars are spent annually on maintaining animal facilities, purchasing animals, and conducting the tests themselves. This massive expenditure covers everything from the specialized infrastructure required for housing millions of laboratory animals to the salaries of personnel and the costs of regulatory compliance. The blog emphasizes that these figures often exclude the billions more spent on failed drug candidates due to poor translation from animal models to humans, highlighting that the current animal-based testing paradigm represents a significant financial drain on the global research and pharmaceutical industry. ↩︎

Cao Y, Polacheck W, New Approach Methodologies: What Clinical Pharmacologists Should Prepare For, Clinical Pharmacology & Therapeutics, 2025
In this 2025 perspective, the authors argue that clinical pharmacologists must urgently adapt to the rising implementation of New Approach Methodologies (NAMs), which replace traditional animal models with human-relevant tools like organ-on-chips, advanced in silico simulations, and human cell-based assays. They emphasize that this regulatory shift is not merely an ethical upgrade but a critical evolution in drug development, promising to resolve the “species barrier” that often leads to drug failure in human trials. They call for pharmacologists to master these diverse NAMs to better predict human pharmacokinetics and toxicity early in the pipeline, thereby streamlining the path to safer, more effective therapies while reducing reliance on animal data. ↩︎ ↩︎

McCarthy J, Bailey J, Baron R, Krebs CE, Singer M, Baker E, Creating training opportunities in new approach methodologies for early-career researchers, NAM Journal, 2025
The paper addresses the critical shortage of skilled professionals capable of implementing New Approach Methodologies (NAMs), highlighting the urgent need for structured training programs tailored to early-career researchers. The authors argue that the rapid transition away from animal testing requires a workforce fluent in non-animal tools such as organ-on-chips, advanced in silico models, and human cell-based assays. They propose collaborative educational frameworks to bridge the knowledge gap, ensuring that the next generation of scientists can effectively design, validate, and interpret NAM data, thereby accelerating the adoption of ethical and efficient drug discovery pipelines. ↩︎